Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
40%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Other(1)

Detailed Status

Completed2
Active, not recruiting1
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 32 (50.0%)

Trials by Status

active_not_recruiting120%
completed240%
unknown120%
recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911
active_not_recruitingphase_3

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT05900141
unknown

Managed Access Programs for TQJ230, Pelacarsen

NCT07000695
completedphase_1

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

NCT05026996
completedphase_1

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

NCT05337878

Clinical Trials (5)

Showing 5 of 5 trials
NCT06813911Phase 3

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Recruiting
NCT05900141Phase 3

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Active Not Recruiting
NCT07000695

Managed Access Programs for TQJ230, Pelacarsen

Unknown
NCT05026996Phase 1

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Completed
NCT05337878Phase 1

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5